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Rapamycin, an allosteric inhibitor of the mTOR kinase, increases longevity in mice in a
sex-specific manner. In contrast to the widely accepted theory that a loss of proteasome
activity is detrimental to both life- and healthspan, biochemical studies in vitro reveal that
rapamycin inhibits 20S proteasome peptidase activity. We tested if this unexpected finding
is also evident after chronic rapamycin treatment in vivo by measuring peptidase activities
for both the 26S and 20S proteasome in liver, fat, and brain tissues of old, male and female
mice fed encapsulated chow containing 2.24mg/kg (14 ppm) rapamycin for 6 months.
Further we assessed if rapamycin altered expression of the chaperone proteins known
to interact with the proteasome-mediated degradation system (PMDS), heat shock factor
1 (HSF1), and the levels of key mTOR pathway proteins. Rapamycin had little effect on
liver proteasome activity in either gender, but increased proteasome activity in female
brain lysates and lowered its activity in female fat tissue. Rapamycin-induced changes in
molecular chaperone levels were also more substantial in tissues from female animals.
Furthermore, mTOR pathway proteins showed more significant changes in female tissues
compared to those from males. These data show collectively that there are divergent
tissue and sex effects of rapamycin on the proteasome-chaperone network and that
these may be linked to the disparate effects of rapamycin on males and females. Further
our findings suggest that rapamycin induces indirect regulation of the PMDS/heat-shock
response through its modulation of the mTOR pathway rather than via direct interactions
between rapamycin and the proteasome.
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INTRODUCTION
Rapamycin, an allosteric inhibitor of mechanistic (mammalian)
target of rapamycin (mTOR) reportedly increases longevity in
mice even when given at an advanced age as an encapsulated for-
mulation in chow. This effect is significantly greater in females
(Miller et al., 2014). The biological mechanism and relevance
of this sex divergence in response to rapamycin is unclear.
Surprisingly, rapamycin has also recently been shown to be an
allosteric inhibitor of proteasome activity in vitro (Osmulski and
Gaczynska, 2013). Further, 20S proteasome activity is reduced
in liver tissues of elderly (25 month old) mice treated with
rapamycin for 6 months when compared to control animals
(Zhang et al., 2014a). However, gene expression studies under-
taken in tissues harvested from the same animals showed equiv-
ocal effects on proteolytic pathways with differentially expressed
genes linked to these pathways both up-regulated and also down-
regulated (Fok et al., 2014). Down-regulated proteolytic pathways
are at variance with the widely accepted theory that the decline
in functionality during aging is linked to an accrual of dam-
aged or misfolded proteins (Ross and Poirier, 2004; David et al.,
2010). This breakdown in proteostasis during aging is attributed
at least in part to an age-associated decline in the efficiency of
the proteolytic machinery (Rodriguez et al., 2010; Grimm et al.,
2012). This leads to the concomitant accrual of aggregation-prone
cytotoxic proteins that underlie many age-associated pathologies
(Bucciantini et al., 2002; Ross and Poirier, 2004).
Age-related changes contributing to compromised protea-
some and autophagy function in short-lived species include
decreased transcription of some catalytic subunits, altered pro-
teasome subcellular distribution, disruption of lysosomal control,
and reduced degradative capacity of both proteolytic machiner-
ies (Ferrington et al., 2005; Massey et al., 2006; Rodriguez et al.,
2010). In contrast to these declines in proteolytic degradation
processes, the proteasome-mediated protein degradation system
(PMDS), that includes both ubiquitin-dependent and indepen-
dent proteasome machinery and associated molecular chaper-
ones, is more robust in naturally long-lived species (Rodriguez
et al., 2012; Edrey et al., 2014), long-lived mutants (Kruegel et al.,
2011), calorically-restricted animals (Bonelli et al., 2008), and
centenarians (Chondrogianni et al., 2000). As such it appears hard
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to reconcile a decline in proteasome function with rapamycin-
induced extended longevity.
The 20S core when doubly capped by 19S regulatory particles
is called the 26S proteasome and is primarily responsible for ubiq-
uitinylated protein degradation and the bulk of PMDS related
proteolytic activity (Demartino and Gillette, 2007). While 20S
proteasomes can exist un-capped in vivo, they are mostly inactive
and contribute only 20–30% of the total proteasome content in a
cell (Babbitt et al., 2005). The 19S regulatory caps through a com-
bination of ATP-dependent (RPT) and ATP-independent (RPN)
subunits mediate substrate uptake, by unfolding, deubiquitiny-
lating, and moving proteins through to the 20S core (Demartino
and Gillette, 2007). Upstream trafficking of substrates to the pro-
teasome is partially controlled by the heat-shock protein (HSP)
family of molecular chaperones. HSP70/72 together with its co-
chaperones may have a key regulatory role in PMDS and pro-
longed efficient function in long-lived species (Grune et al., 2011;
Rodriguez et al., 2014). Further, the smaller molecular chaperone,
HSP25, has been implicated in the mitigation of protein aggre-
gation in vertebrates (Goldbaum et al., 2009). While chaperone
interactions in the PMDS may be critical for maintained protein
homeostasis, recently the drug rapamycin has been shown to sup-
press the heat-shock response in cell culture (Chou et al., 2012),
yet nevertheless facilitates prolonged healthspan and extended
longevity in vivo (Harrison et al., 2009; Miller et al., 2011, 2014;
Zhang et al., 2014a).
We question whether this observation of reduced protea-
some activity (Osmulski and Gaczynska, 2013; Zhang et al.,
2014a) and suppression of the heat-shock response seen in
vitro (Chou et al., 2012), is observed in vivo especially in
light of rapamycin-mediated transcriptional regulation of cer-
tain proteasome-related genes (Fok et al., 2014). If this is the
case, it may reveal that the mechanisms facilitating the increase in
healthspan and longevity seen by improved protein homeostasis
are independent of rapamycin-induced longevity and healthspan.
We test the hypothesis that rapamycin counters the deleterious
effects of aging in C57BL/6 mice through differentially sup-
pressing the PMDS. We also ask if there are sex and/or tissue
differences in in the various proteasome activities and molecu-
lar chaperone responses to rapamycin and whether changes in
the mTOR pathway elucidate a mechanism for this rapamycin
induced modulation of proteolytic function and lifespan.
METHODS
ANIMALS
Care of animals followed UT Health Science Center Institutional
Animal Care and Use Committees approved procedures. Specific
pathogen-free C57BL/6 mice were purchased from the National
Institutes of Health colony reared in the Charles River
Laboratories at 19 months of age. Mice were maintained under
barrier conditions by the UTHSCSA Nathan Shock Center Aging
Animal and Longevity Assessment Core and started on the
FIGURE 1 | Changes in chymotrypsin-like (ChTL) and trypsin-like (TL)
26S proteasome activity in rapamycin-treated lysates from old animals
depended upon the tissue type and sex of the animals tested. Significant
increase was observed for both ChTL (3X) and TL (2X) 26S proteasome
activities in whole brain lysates from female animals only. No significant
effects were evident in male brains. Liver TL activity declined (0.8X) with
rapamycin treatment in males. Rapamycin treatment led to a decline in
visceral fat ChTL (0.7X) and TL (0.7X) activity in females but not in males.
PGPH activity did not show any significant differences between treated or
untreated animals in any of the tissues examined. The y-axis indicates net
proteasome activity in pmol/min/μg lysate for each of the respective activities
measured. Statistically significant differences (Two-Way ANOVA, p < 0.05)
comparing treatment vs. vehicle (∗) and/or male vs. female untreated (#) or
male vs. female treated ($) are indicated (n = 5 brain, fat, n = 6 liver).
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Table 1 | Rapamycin-influenced changes in markers of proteasome,
chaperone, and mTOR pathway in old male and female brain, liver,




Female Male Female Male Female Male
brain brain liver liver visceral visceral
fat fat
ChTL UP – – – DN –
TL UP – – DN DN –
PGPH – – – – – –
α7 – – DN – DN –
Rpt5 UP – – – DN –
HSF1 – – – DN DN –
HSP90 – – DN DN DN –
HSP70 UP – – DN DN DN
HSP40 – – – DN DN –
CHIP UP – DN DN – –
HSP25 UP – – – DN DN
mTOR – – – – – –
p-mTOR UP – – – – –
AKT UP – – UP – –
p-AKT UP – – – – UP
rp-S6 UP – – – – –
p-rpS6 UP – – – DN –
4EBP1 UP – – UP DN –
p-4EBP1 – – UP UP – –
“UP” indicates a rapamycin-dependent significant increase. “DN” represents a
rapamycin-dependent significant decrease.
rapamycin/eudragit control diet at ∼19 months of age. Six
months later at ∼25 months of age, the ad libitum fed animals
were anesthetized with isofluorane, euthanized by cardiac exsan-
guination and the tissues immediately excised and flash frozen
in liquid nitrogen. All the tissues from these animals that were
not fasted prior to sacrifice were stored at −80◦C until used in
analyses.
DIET PREPARATION
Mice were fed a diet containing either encapsulated rapamycin or
empty capsules (eudragit control). Microencapsulated rapamycin
or empty microcapsules were incorporated into Purina 5LG6
diet. The rapamycin diet was prepared at 14 ppm using meth-
ods described by Harrison et al. (2009) and blood levels checked
to confirm appropriate dosing. Data pertaining to the rapamycin
blood levels, lifespan, and healthspan effects of these animals have
been previously published (Fok et al., 2014; Zhang et al., 2014a).
LYSATES
Mouse tissue (∼50–100mg fat, ∼15–30mg liver, 100–200mg
brain) was cryofractured under liquid nitrogen with a mor-
tar and pestle. Powdered fat was lysed by homogenization
in 2× dry weight in Protein Homogenization Buffer (50mM
HEPES, pH 7.6, 150mM sodium chloride, 20mM sodium
pyrophosphate, 20mM ß-glycerophosphate, 10mM sodium flu-
oride, 2mM sodium orthovanadate, 2mM ethylenediaminete-
traacetic acid, 1% IGEPAL, 10% glycerol, 1mM magnesium
chloride, 1mM calcium chloride, 1mM phenylmethylsulfonyl
fluoride, and one tablet/10ml Complete Mini (EDTA free) pro-
tease inhibitor tablets from Roche) for Western blots and in
Re-suspension Buffer (RSB) (10mM HEPES, pH 6.2, 10mM
NaCl, 1.4mM MgCl2) without protease inhibitors at a weight
per volume ratio of 1 g of tissue to 2mL of buffer for pep-
tidolytic assays. The RSB buffer was supplemented with the
addition of 1mM ATP, 0.5mM DTT, 5mM MgCl2 to help main-
tain intact 26S subassemblies (Liu et al., 2006). Powdered liver
was lysed by homogenization in 5× dry weight in modified
RIPA Buffer (150mM sodium chloride, 50mM Tris-HCl, pH
7.4, 1mM ethylenediaminetetraacetic acid, 1mM phenylmethyl-
sulfonyl flouride, 1% Triton X-100, 1% sodium deoxycholic
acid, 0.1% sodium dodecyl sulfate, 1μM Bortezomib protea-
some inhibitor, and one tablet/10ml protease and phosphatase
inhibitor mini tablets (Thermo Fisher Scientific, Waltham, MA,
USA) for Western blots. For peptidolytic assays, liver powder
was lysed in RSB without protease inhibitors and with ATP sup-
plemented as described above at a weight per volume ration
of 1 g of tissue to 5mL of buffer. Brain tissue was separated
and lysed in RSB containing the protease/phosphatase cocktail
tablet described above (Thermo Fisher Scientific) for Western
blot analyses or RSB without protease inhibitors containing the
ATP supplement for peptidolytic assays. Debris was cleared by
centrifugation (3000 g for 12min). The Bio-Rad Protein Assay
(Bio-Rad Life Sciences, Hercules, CA) or BCA Assay (Thermo
Fisher Scientific) was used to determine protein concentrations.
PEPTIDOLYTIC ACTIVITY
In each assay 20μg of whole tissue lysates were incubated
with 100μM of substrate specific for the type of proteasome
activity. A saturating concentration of proteasome inhibitor
N-(benzyloxycarbonyl) leucinyl-leucinyl-leucinal (MG132) was
added to parallel samples. The difference of the fluorescence
released with and without inhibitor was used as a measure
of the net peptidolytic activity of proteasome as previously
described using model peptide substrates to represent cleav-
age after hydrophobic (Chymotrypsin-like; ChTL) residues, basic
residues (Trypsin-like; TL) and acidic residues (Post-glutamyl,
peptide-hydrolizing; PGPH) (Rodriguez et al., 2010).
WESTERN BLOTS
Tissue lysates were separated using a 4–12% SDS-PAGE (Biorad
Life Sciences) and transferred to nitrocellulose membranes
(Biorad Life Sciences). The membranes were probed with anti-
bodies against the following proteasome and chaperone pro-
teins: HSP90 (mouse mAb, SPA831, 1:20K), HSF1 (rabbit pAb,
SPA901, 1:5K), HSP70/72 (mouse mAb, SPA810, 1:10K), HSP40
(HDJ1) (rabbit pAb, SPA400, 1:2.5K), HSP25/HSPB1 (rab-
bit pAb, SPA801, 1:10K), α7 (mouse mAb, PW8110, 1:5K,),
RPT5 (mouse mAb, PW8310, 1:5K) (Enzo Life Sciences,
Plymouth Meeting, PA, USA) and Carboxyl-terminus of HSP70
Interacting Protein (CHIP) [rabbit mAb(C3B6), #2080, 1:5K]
(Cell Signaling Technology, Inc., Danvers, MA, USA). Antibodies
against GAPDH (mouse mAb, G8795, 1:30K) (Sigma-Aldrich,
St. Louis, MO, USA) were used as a loading control. For
mTOR pathway proteins, the following antibodies were used
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FIGURE 2 | Female Brain Lysates showed a rapamycin-dependent
increase in 26S proteasome. (A) Representative zymogram of
Chymotrypsin-like (ChTL) proteasome activity after native gel electrophoresis
of 50μg of brain lysate from control and rapamycin-treated old male and
female animals. (B) Quantitation of zymogram showed that there was a
treatement-induced increase in 26S-specific ChTL proteasome activity in
female brain lysates (n = 4, ∗p < 0.05 Two-Way ANOVA). (C) Representative
immunoblot of α7 proteasome subunit after transfer from native gel.
(D) Similarly, α7 subunit showed a 26S-specific change (increase in females,
decrease in males; ∗p < 0.05, ∗∗p < 0.01; n = 4, Two-Way ANOVA) in
assembled proteasome content. It did not seem that change in male
proteasome content was sufficient to influence a change in activity.
all at 1:1K dilutions: mTOR (rabbit pAb, #2972), phospho-
mTOR (Ser2448) (rabbit pAb, #2971), AKT (rabbit pAb, #9272),
phospho-AKT (Ser473) (rabbit, pAb, #9271), S6 ribosomal pro-
tein (mouse mAb (54D2), #2317), phospho-S6 ribosomal protein
(Ser240/244) (rabbit pAb, #2215), 4EBP1 (rabbit pAb, #9452) and
phospho-4EBP1 (Thr37/46) (236B4) (rabbit mAb, #2855) (Cell
Signaling Technology). Either the GAPDH antibody used above
or pan-Actin (mouse mAb, MS-1295-P0, 1:20K) (Thermo-Fisher
Scientific) was used as a loading control.
Primary antibodies were detected using anti-mouse IRDye
680LT, or anti-rabbit IR Dye800 CW (Li-Cor, Lincoln, NB, USA)
conjugated antibodies. Secondary antibodies were incubated at
1:10K (anti-rabbit) or 1:20K (anti-mouse) for 2 h at room tem-
perature and images were captured and subsequently quantified
using the Odyssey Imaging System (Li-Cor) by quantifying fluo-
rescent signals as Integrated Intensities (I.I. K Counts) using the
Odyssey Infrared Imaging System, Application Version 3.0 soft-
ware. We used a local background subtraction method to subtract
independent background values from each box, more specifically,
the “median” background function with a 3 pixel width border
above and below each box was subtracted from individual counts.
We calculated ratios for each antibody against the pan-actin or
GAPDH loading control using I.I. K Counts. The respective anti-
body to pan-actin or GAPDH ratio was then used to calculate
phosphorylated protein to total protein ratio were applicable.
NATIVE GEL ELECTROPHORESIS
In this current study, we use an ATP-reconstituting system to
maintain the integrity of the 26S proteasome (Liu et al., 2006),
however it cannot be ruled out that the fluorogenic proteasome
assay measures total proteasome activity for all the proteasome
subassemblies, nor does it directly report ubiquitin-dependent
activity of the whole 26S. With that caveat, however, we supple-
ment this reliable indirect measure with in-gel assays on native
gels.
Proteasome ChTL function was also measured using Native
Gel Electrophoresis. This technique enabled us to discriminate if
26S or 20S proteasome activity predominated, the relative quan-
tities of both the double-capped and uncapped proteasome and
proteasome specific activities. Fifty micrograms of fractionated
lysate from each of the sample groups prepared as described
in Subcellular Fractionation above (q.v) were run on a 3–12%
non-denaturing, gradient polyacrylamide gel (Life Technologies,
Carlsbad, CA). The gel was run at 30V for 30min in a 4◦C cold
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FIGURE 3 | Liver Lysates revealed potential rapamycin-dependent
declines in proteasome activity. (A) Representative zymogram of
Chymotrypsin-like (ChTL) proteasome activity after native gel
electrophoresis of 50μg of liver lysate from control and
rapamycin-treated old male and female animals. (B) Quantitation of
zymogram showed that there was a treatement-induced decrease in
26S-specific ChTL proteasome activity in female brain lysates (n = 4,
∗p < 0.05 Two-Way ANOVA). (C) Representative immunoblot of α7
proteasome subunit after transfer from native gel. (D) The calculated
amounts of the α7 subunit showed significant decreases at both the
26S (females) and 20S sites (males and females) (∗p < 0.05, ∗∗p < 0.01;
n = 4, Two-Way ANOVA).
cabinet, thereafter the voltage was increased to 35V for 1 h, 50V
for 1 h and further increased to 75V for three more hours (Elasser
et al., 2005; Tai et al., 2010).
Peptidolytic activity of proteasomes was detected after incu-
bating the gels in a Suc-LLVY-MCA substrate dissolved in 50mM
Tris pH 8.0, 5mMMgCl2, 1mMDTT, 2mMATP, and 0.02% SDS
for 15, 30, and 60min at 37◦C. Proteasome bands were identi-
fied by the release of highly fluorescent, free AMC (Elasser et al.,
2005; Vernace et al., 2007; Rodriguez et al., 2012). Fluorescence
was quantitated using ImageJ software (http://imagej.nih.gov/
ij/). Following the in-gel assay, the protein from the gel was
transferred to nitrocellulose using the i-blot transfer apparatus
(Life Technologies) and subjected to Western blotting analyses
using the α7 antibody described above to determine where the
26S and 20S proteasome complexes lay. The IRDye conjugat-
ing antibodies and the Odyssey Imaging System (Li-Cor) were
used to quantitate the amounts of α7 signal (See Western Blots
above).
STATISTICAL ANALYSES
Prism 5 (GraphPad Software, Inc.) was used to analyze and graph
the mTOR pathway Western blot data. An unpaired two-tailed
t-test or MannWhitney test was used to obtain p-values. P-values
below 0.05 were considered significant. Proteasome and chap-
erone data was analyzed with Sigma Plot (v.11) using Two-Way
ANOVA. Statistical significance was set at the p < 0.05 level with
Tukey and Holm-Sidak corrections to counteract the probability
of false positives. Cluster Analysis was performed using Cluster
3.0 and Treeview v 1.16r2 to generate output (open source code
http://bonsai.hgc.jp/~mdehoon/software/cluster/; University of
Tokyo, 2002). Data were log transformed to normalize the activity
and protein expression data, and the cluster was generated using
the groupmedians and hierarchical clustering with an uncentered
Pearson Correlation to generate a complete linkage to create the
most unbiased set of clusters (Yeung and Ruzzo, 2001; De Hoon,
2002).
RESULTS
RAPAMYCIN-TREATED FEMALES SHOWED INCREASES IN BOTH
CHYMOTRYPSIN-LIKE AND TRYPSIN-LIKE 26S PROTEASOME ACTIVITY
IN BRAIN, BUT NOT IN LIVER OR VISCERAL FAT
Peptidolytic activity of the proteasome was measured in old
(25 month) male and female, rapamycin-treated and untreated,
brain, liver, and visceral fat lysates using model peptide substrates
specific for each of the three types of catalytic sites. The core par-
ticle contains three cleavage sites that degrade polypeptides or
unfolded proteins severing peptide bonds on the carboxyl side
of hydrophobic (“chymotrypsin-like”; ChTL), basic (“trypsin-
like”; TL), or acidic (“peptidylglutamyl peptide hydrolyzing” or
“caspase-like”; PGPH) residues (Demartino and Gillette, 2007).
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FIGURE 4 | Female Fat Lysates also showed rapamycin-influenced
declines in proteasome activity. (A) Representative zymogram of
Chymotrypsin-like (ChTL) proteasome activity after native gel electrophoresis
of 50μg of visceral fat lysate from control and rapamycin-treated old male
and female animals. (B) Quantitation of the zymogram revealed that there
was a treatment-dependent decrease in female 26S ChTL activity (n = 4,
∗p < 0.05 Two-Way ANOVA). (C) Representative immunoblot of α7
proteasome subunit after transfer from native gel. (D) The α7 subunit
quantitation indicated significant decreases in both female 26S and 20S
content (∗p < 0.05, ∗∗p < 0.01; n = 4, Two-Way ANOVA).
To determine net proteasome activity, assays were run in paral-
lel with and without the proteasome inhibitor MG132. Divergent
responses were evident with regards to treatment, sex, and pepti-
dolytic activities (Figure 1; summarized in Table 1). In untreated
animals, males showed significantly higher ChTL activity in brain
(p = 0.01), liver (p = 0.002), and fat (p = 0.03) (Figure 1, top
panels) than observed in females. TL activity, while still higher
for males in liver (p = 0.009), was the same in brain and higher
in females visceral fat (p = 0.02). PGPH activity was higher in
lysates from female animals compared tomales in both brain (p =
0.03) and fat (p = 0.01), but in liver, PGPH activity was higher
in untreated males compared to females (p = 0.003) (Figure 1,
bottom panels).
Rapamycin effects were also tissue-specific but in general pro-
teasome activity in females was more responsive to rapamycin
treatment. In whole brain tissue lysates males showed no change
in proteasome activity, whereas in females, the change in pro-
teasome activity was significant, being nearly 3-fold higher for
ChTL (p = 0.0009) and 2-fold higher for TL (p = 0.0005) sub-
strates in treated compared to untreated samples (Figure 1, top
left). In the liver lysates only male TL activity changed sig-
nificantly, with a 20% decline in activity in the rapamycin
treated (p = 0.02) (Figure 1, middle). Finally, proteasome activ-
ity from visceral fat lysates showed significant declines in ChTL
(p = 0.05) and TL (p = 0.01) activities of 30% in samples
from treated females compared to controls. Activity in male
fat lysates did not change with treatment (Figure 1, right pan-
els). Rapamycin treatment had no effect on PGPH activity in
either sex or in any of the tissues tested (Figure 1, left panels).
Interestingly, ChTL activity showed the greatest sexual dimor-
phism with sex-differences evident in the activities of samples
from both rapamycin-treated and untreated controls. Activity
was higher in male control samples, whereas females showed
the higher activity in rapamcyin treated samples (Figure 1, top
left).
Native gel electrophoresis has been used to determine if
the proteasome remains intact in a higher molecular weight
form (i.e., 26S) or exists disassembled (20S) (Elasser et al.,
2005; Rodriguez et al., 2012). We used this technique to
determine if either the 20S or 26S proteasome assembly, was
affected by rapamycin treatment or showed sex-specific differ-
ences (Figures 2–4). In tissue lysates from female mouse brains,
the in-gel assay measuring ChTL activity (Figures 2A,B) showed
a significant increase in 26S proteasome activity in a rapamycin-
dependent manner (p = 0.02), but not in 20S activity. In con-
trast ChTL activity in male mouse brains did not change (p >
0.05). The immunblot analyses of α7 (Figures 2C,D) revealed
that the 26S proteasome content of this protein significantly
increased in brain lysates of rapamycin treated female mice (p =
0.003). Interestingly, the proteasome α7 decreased significantly in
rapamycin-treated male mice brain samples compared to those of
the male control group (Figures 2C,D; p = 0.02), though this did
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FIGURE 5 | Both proteasome subunits and proteasome-related
chaperones in brain, liver, and visceral fat lysates revealed tissue and
sex dependent treatment-related changes. Changes in protein expression
as measured by Western blots relative to GAPDH, and normalized to old
control in brain lysates from old (25 mo) male and female rapamycin-fed mice
(A) indicated a female-specific, treatment-related increase for HSP72,
HSP40, CHIP, HSP25, and RPT5. All these proteins also showed
sex-dependent differences as well. In liver lysates (B) both sexes showed a
treatment-related decline in all proteins tested except for HSP25 and RPT5.
There was only a significant sex difference in α7. In visceral fat lysates
(C) females again showed a treatment-related change most strikingly for the
proteasome markers α7 and RPT5. Visceral fat showed significant
sex-dependent differences in all proteins tested except for HSP25. Significant
differences between male and female pairs (n = 3 brain, n = 5 fat, n = 6 liver;
Two-Way ANOVA, p < 0.05) are indicated by (∗) treatment-related change or
(#) sex-dependent change.
not reflect on activity. 20S proteasome content did not change for
either sex.
Zymograms for 26S proteasome activity showed a significant
decline in both liver (Figures 3A,B) and fat (Figures 4A,B) tis-
sue lysates of rapamycin-treated females (p = 0.008 brain, p =
0.009 fat) with no change in proteasome activity for either
sex at the 20S site. A significant decline in α7 protein content
occurred in 26S proteasomes measured in liver samples from
rapamycin-treated females (p = 0.004). Further, 20S α7 pro-
tein content declined in both male (p = 0.02) and female liver
samples (p = 0.001) (Figures 3C,D). Proteasome content in fat
tissue lysates (α7) also decreased significantly for both the 26S
(p = 0.003) and 20S (p = 0.04) sites of treated female sample
whereas α7 content did not change in the fat samples from
males.
LEVELS OF PROTEASOME-RELATED CHAPERONES CHANGED MORE IN
TREATED FEMALES THAN IN TREATED MALES
Western blot analyses using a panel of antibodies represent-
ing major chaperone families and key proteasome subunits
was undertaken in the tissues harvested from rapamycin-fed
and Eudragit-(vehicle) fed controls. Tissues from three male
and three female 25 month old mice were analyzed. In lysates
from male samples, rapamycin had no effect on chaperone lev-
els (Figure 5A). In female brain lysates, the levels of HSP70,
CHIP, and HSP25 proteins increased in treated samples com-
pared to controls (Figure 5A). Further, the 19S cap protein
RPT5 also showed a higher protein content in these brain
lysates from rapamycin-treated females (Figure 5A). Proteins
were normalized to GAPDH whose mRNA is eIF4E insensitive
and would not change with rapamycin treatment (Livingstone
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FIGURE 6 | Treatment with rapamycin altered expression of key
proteins of the mTOR pathway in female brain lysates. (A) Basic
schematic of the relationship of the proteins tested (highlighted in red)
to mTOR (R1 indicates mTORC1-dependent branch while R2 indicates
the mTORC2-dependent branch). (B) Changes in protein expression of
these markers of the mTOR pathway measured in brain lysates from
25 month-old male and female mice (rapamycin-fed vs. control) and
quantified Integrated Intensities (I.I. K Counts) relative to GAPDH (I.I. K
Count Ratio) (C) showed that rapamycin influenced change in mTOR
itself and both proteins upstream of mTOR (AKT) as well as its
downstream targets (rpS6 and 4EBP1). Both total and phosphorylated (p)
forms are presented as well as the ratio of the phosphorylated vs. the
total protein. Significant p-values as derived by Two-Way ANOVA (n = 3)
using Prism GraphPad Software is indicated for each set of proteins.
et al., 2010), These data are indicative of an increased 26S pop-
ulation and RPT5 levels correlated with an increase in ChTL
and TL proteasome activity in brain lysates (Figure 1). In liver,
with the exception of HSP25 (which did not change), there
was a decline in heat shock proteins in both sexes with treat-
ment (Figure 5B). While α7 levels also decreased in males
and females, this did not correlate with any loss in protea-
some activity (Figures 1, 5B). In visceral fat, HSF1 as well as
HSP90, HSP70, HSP40, and HSP25 decreased significantly in
samples from treated female animals (Figure 5C). Both RPT5
and α7 also showed protein declines in fat samples from
rapamycin-treated females that correlated with a decline in ChTL
and TL proteasome activity. Interestingly, samples from treated
males showed declines in CHIP, HSP, and HSP25 (Figure 5C).
Lastly, HSP90, HSP70, and RPT5 showed significant differences
between males and females sample in their immuno-detection
(Figure 5C).
mTOR PATHWAY MARKERS RESPONDED TO RAPAMYCIN TREATMENT
IN FEMALES BUT THESE CHANGES WERE ALSO TISSUE DEPENDENT
To examine for a correlation between the changes in protea-
some activity and chaperone profile with the mTOR pathway, we
immunoassayed a subset of mTOR pathway proteins and their
phosphorylated forms (p) in brain, liver, and visceral fat lysates
from old male and female, rapamycin-fed animals and compared
to similarly aged controls relative to Actin (also insensitive to
rapamycin) or GAPDH (Livingstone et al., 2010) (Figure 6B).
Female rapamycin-treated brains had higher levels of p-mTOR
(Ser2448), and both total and phosphorylated AKT (Ser473) and
rpS6 (Ser240/244). We also observed an increase in total 4EBP1
and unchanged p-4EBP1 (Thr36/47) levels which led to signifi-
cant decline in the ratio of p-4EBP1/4EBP1 (Figure 6C). In male
lysates there was no significant difference in the phosphorylated
or total protein expression of these four mTOR pathway proteins,
with rapamycin-treatment (Figures 6B,C).
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FIGURE 7 | Liver lysates from female C57BL6 mice did not show a clear
pattern of change in mTOR signaling. (A) Liver lysates from 25 month
female rapamycin-treated and control animals were analyzed by Western blot
for several mTOR-pathway related proteins and quantified using I.I. K Counts
relative to pan-Actin or GAPDH (B). P-values (unpaired t-test, Prism
GraphPad) are indicated above each dot plot (n = 6).
Rapamycin had little effect on protein expression of
mTOR related proteins in liver tissue (Figures 7, 8). Only
p-4EBP1 (Thr36/47) in liver lysates of females was sig-
nificantly higher with rapamycin (Figures 7A,B) whereas
in liver lysates from males, rapamycin induced increased
expression of both p-4EBP1 (Thr36/47) and total 4EBP1
(Figures 8A,B) as well as total AKT. The latter change
led to a lower ratio of p-AKT (Ser473) to total AKT
(Figure 8B).
Visceral fat lysates from rapamycin-treated females showed
a trend toward a decrease in p-AKT (Ser473), total mTOR
and downstream effectors p-rp-S6 (Ser240/244) and total
4EBP1 (Figures 9A,B). These rapamycin mediated declines in
protein expression led to altered ratios of the phosphory-
lated form to the total proteins (Figure 7B). The effects of
rapamycin on the expression of these proteins were attenuated
in males. Only phosphorylated AKT (Ser473) and the ratios
of p-mTOR (Ser2448) to total mTOR significantly increased
(Figures 10A,B).
CLUSTER ANALYSES REVEALED THAT BRAIN PROTEASOME ACTIVITY
IS MOST INFLUENCED BY RAPAMYCIN
Table 1 summarizes the observed rapamycin-mediated changes
in proteasome activity, chaperones, and mTOR pathway proteins
tested in this study. To determine whether the combined protea-
some activities, chaperone, and mTOR pathway data assembled
into common patterns of rapamycin-associated changes, cluster
analyses were performed (Figure 11). First, proteasome activity
and proteasome-related chaperones were clustered (Figure 11A).
Cluster analysis revealed that groups separated by tissue type,
weighted toward the higher levels of proteasome activity in liver
and brain. These groups were further divided in the analysis by
sex, but treatment was indistinguishable (Figure 11A). In this
comparison, two distinct clusters formed. The first major clus-
ter consisted of proteasome activity, the 19S ATPase RPT5 and
HSF1in one sub-cluster with α7 and HSP25 in another. The
second major cluster showed that the large chaperones (HSP90
and HSP70) and the HSP70 co-chaperones HSP40 and CHIP
sub-divided into sub-clusters (Figure 11A).
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FIGURE 8 | Liver lysates from male C57BL6 mice also did not
show a clear pattern of change in mTOR signaling.
(A) Western blots from lysates from 25 month-old males and
quantitation using I.I. K Counts relative to pan-Actin or GAPDH
(B). P-values (unpaired t-test, Prism GraphPad) are indicated above
each dot plot (n = 6).
The mTOR pathway proteins were added into the next clus-
ter analysis (Figure 11B). This revealed that rapamycin-treated
female brain and treated male liver formed two distinct groups.
Three clusters formed in this analysis, with the mTOR path-
way proteins 4EBP1 and p-AKT joining the “proteasome activity
cluster” with the same proteins associated in the first Chaperone-
Proteasome analysis from panel A (RPT5, α7, HSP25, and HSF1).
A second cluster containing HSP90 and the co-chaperones HSP40
and CHIP also contained p-4EBP1, AKT, and rpS6 (Figure 11B).
The last cluster in this analysis was characterized by low p-mTOR
and low p-rpS6 (brain), and associated with HSP70 and total
mTOR (Figure 11B).
DISCUSSION
In this study we evaluated if rapamycin-mediated changes in
mTOR signaling and the ubiquitin proteasome system (i.e., pro-
teasome activity and content and associated protein levels various
chaperones) correlated with the sexually dimorphic effects of
rapamycin on lifespan. Rapamycin-induced changes in protea-
some activity and expression of the various molecular chaperones
and mTOR pathway proteins were both sex- and tissue-specific
(Figure 11). Rapamycin effects are readily apparent from both
individual variables and cluster analyses (Figure 11). The latter
were generated by applying multiple peptidolytic assays and asso-
ciated chaperone proteins as well as a sampling of mTOR pathway
proteins across the three tissues harvested from the same indi-
viduals. Cluster analyses reveal there are interactions between
the proteasome-chaperone network and the mTOR pathway.
Rapamycin treatment led to elevated proteasome activities in the
brain of females, potentially promoting the removal of oxida-
tively damaged and misfolded proteins and creating improved
proteostasis in female mice that are likely to contribute to the
better protection of their brains against environmentally medi-
ated (e.g., oxidatively damaged/ glucose crosslinking) protein
aggregation. Better protection of the female brain may be an
evolutionary life-history tradeoff and these traits may possibly
vary with reproductive status (non-reproductive pregnant, lacta-
tion). Improved proteostasis and concomitant neuroprotection in
the brains of rapamycin treated females supports previous stud-
ies using genetically engineered mouse models of Alzheimer’s
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FIGURE 9 | The phosphorylation state of downstream mTOR
pathway markers changed significantly in visceral fat lysates from
rapamycin-treated females. Measuring protein content of several
mTOR pathway markers analyzed from visceral fat lysates taken from
25 month rapamycin-fed and control female mice via immunoblot
(A) quantified using I.I. K Counts relative to pan-Actin (B) revealed a
decrease in p-rp-S6 which also lowered the ratio (phosphorylation state)
of p-rpS6 to total rp-S6. Total 4EBP1 also declined, increasing the
phosphorylation state. P-values, derived using Prism GraphPad Software,
are indicated for each dot plot (n = 5).
disease in which rapamycin firstly improved cognition and when
subjected to a chronic high sugar diet prevented the accrual of
protein aggregates, plaques and neurofibrillary tangles (Orr et al.,
2014).
RAPAMYCIN EFFECTS ARE TISSUE-SPECIFIC
Contrary to a previous data that examined only the 20S cat-
alytic core ChTL activity (Zhang et al., 2014a), our extensive study
revealed that rapamycin treatment did not globally suppress the
PMDS or its associated chaperones. Indeed in our current study,
declines in proteasome were observed predominantly in visceral
fat (Figures 1, 4) in contrast the previous study using mice in
the same cohort showed decreases in both heart and liver 20S
ChTL proteasome activity in both sexes of rapamycin-treated
mice (Zhang et al., 2014a). The decline in proteasome activity
in peripheral tissues both in this study and that of Zhang, is in
keeping with in vitro findings that rapamycin can allosterically
inhibit proteasome activity (Osmulski and Gaczynska, 2013)
However, this cannot explain the tissue specific increases in ChTL
and TL proteasome activity in the brains of rapamycin treated
animals.
While ChTL is considered the pivotal peptidolytic activity
of oxidatively damaged proteins, other peptidase activities such
as TL and PGPH activity may be more sensitive to rapamycin.
Female mice treated with rapamycin showed the most diver-
gent responses compared to untreated females for both the ChTL
and TL catalytic sites in fat (decrease) and brain (increase)
(Figure 1). PGPH proteasome activity did not change suggesting
that rapamycin-mediated effects target specific types of proteins
and peptides for cleavage driving changes in proteasome function
rather than a restructuring of the proteasome although there is
some evidence that mTOR signaling can induce proteasome sub-
units through both complex 1 or complex 2 (Lamming et al.,
2014; Zhang et al., 2014b).
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FIGURE 10 | mTOR pathway proteins changedminimally in visceral fat
lysates fromrapamycin-treatedmales.Lysatescreated fromthevisceral fatof
25 month-old rapamycin-fed and control male mice were analyzed via Western
blot (A) and quantified using I.I. K Counts (B) relative to pan-Actin as a loading
control. Only phosphorylated AKT showed a significant change. P-values
(unpaired t-test, Prism GraphPad) are shown above each dot plot (n = 5).
Given that rapamycin is likely to first reach the liver via the
hepatic portal vein and be at its most concentrated there, it
is surprising that of the three tissues examined, the liver was
least sensitive to rapamycin treatment as shown by the peptide
assays (Figure 1). It is possible that rapamycin is metabolized
in such a way in the liver that it has minimal effects on liver
proteasome function. Alternately, as the liver has several path-
ways involving nutrient signaling, a slight perturbation in the
mTOR pathway is likely to be compensated for by other signaling
pathways. Unfortunately, published RNA-sequence analyses data
revealing differentially expressed genes in the transcriptome with
rapamycin were equivocal (Fok et al., 2014) and did not reveal
an obvious explanation for a lack of a change in 26S proteasome
activity or a decline only in 26S TL activity as was seen in males
with treatment (Figure 1). However, the in-gel assay on native
gels did show a decline ChTL activity in lysates from rapamycin-
treated samples from females (Figure 3) and a decline in α7
proteasome content suggesting alterations in liver proteasome
expression and quantity by rapamycin(Zhang et al., 2014a). Given
the low blood titer of C57BL6 compared to the UM-HET3 mice
(∼3–4 ng/L compared to 13.4 ng/L, respectively, after 6 months
of treatment) (Harrison et al., 2009; Zhang et al., 2014a), we
may have only observed effects in tissues that are particularly
sensitive to rapamycin. Also, there definitely seem to be strain-
dependent differences in at least rapamycin uptake or metabolism
which could dictate the effect of the drug on measured
parameters.
RAPAMYCIN DECREASES PROTEASOME ACTIVITY IN VISCERAL FAT
We chose to include fat tissue in our analyses because we hypoth-
esized it may be more sensitive to alterations in mTOR signaling,
being a nutrient storage tissue, and was previously shown to
be responsive male and female mice (Harrison et al., 2009). In
C57BL6 mice, proteasome activity declines with age in adipose
tissue (Dasuri et al., 2011). Our study shows that in old animals,
there is a further reduction in proteolytic activity in visceral fat
harvested from female mice after rapamycin-treatment (Figure 1)
which was supported by a similar observation on native gel
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FIGURE 11 | Cluster analysis shows a proteasome-influenced grouping
by tissue, sex, and then treatment. A heat map showing results of
the cluster analysis of variables including log-transformed peptidolytic
activities and quantities of proteins determined by immuno-blot first
with proteasome activity, proteasome subunits, and several
proteasome-related chaperones together (A), and then with the addition
selected mTOR pathway proteins (B). Groups representing the various
lysates collected from animals treated with rapamycin and corresponding
controls are organized in columns represent cases. Four letter codes
define the groups with the first two in the code representing gender
(OM, Old Male; OF, Old Female). The third letter represents the tissue
(L, Liver; F, Fat; B, Brain), and the forth letter denotes treatment group
(C, Control (Eudragit); R, Rapamycin-treated; i.e., OMFC, Old Male Fat
Control). The three proteasome activity and protein tests are organized
in rows. Results obtained with Cluster 3.0 analysis are shown. Heat
maps were prepared with TreeView v.1.16r2. Color scheme corresponds
to the normalized values of variables where bright green represent the
lowest (approaching −3.0) and bright red the highest (close to +3.0)
values. The lengths of tree branches are proportional to a relative
similarity between variables and between cases.
zymograms (Figure 4). This was accompanied by a treatment-
related reduction in the key proteasome subunits α7 and RPT5
(Figures 4, 5). Thus, rapamycin appears to affect upstream con-
trol of critical genes in the PMDS in visceral fat though at this
time it is unknown whether this effect is transcriptional or trans-
lational. Optimal function of the 26S is dependent on a tightly
regulated ratio of ATPases such as RPT5 in the 19S regulatory
cap (Smith et al., 2011). Alternatively, or in combination with an
upstream regulation of RPT5 and/ or other proteasome ATPases,
rapamycyin has been shown to directly block proteasome activ-
ity in vitro by interfering with the attachment of the 19S cap
(Osmulski and Gaczynska, 2013). A similar mechanism may be
in place in fat tissue whereby the inhibition of mTOR signaling
in adipose tissue may block the binding of the regulatory cap to
the catalytic core and impair proteasome function. Reduction of
the proteasome activity has been shown to induce cytotoxicity,
upregulate cell stress responses, and lead to various pathologies in
other tissues (Goldbaum et al., 2006; Grimm et al., 2012). Taken
together these data suggest that rapamycin-induced declines in
visceral fat PMDS function could be detrimental and contribute
to some of the observed peripheral tissue pathologies associated
with age (Dasuri et al., 2011). For example, the development
of obesity and insulin signaling in type 2 diabetes is influenced
by the PMDS as insulin receptor substrate 1 is inactivated by
degradation through this system (Sun et al., 1999; Chang et al.,
2009). Thus, effects that mimic aging in PMDS function could
substantially contribute to age-related insulin resistance in adi-
pose tissue and other deleterious features associated with both fat
and liver metabolism (Umemura et al., 2014). While we did not
measure changes in insulin signaling in this cohort of animals,
others have shown consistently that rapamycin affects the insulin
pathway in much the same manner in multiple strains of mice
including C57BL6, namely creating glucose intolerance, but caus-
ing insulin sensitivity (Lamming et al., 2013; Orr et al., 2014; Yu
et al., 2014). PMDS could be a potential pathway to explain this
phenomenon.
RAPAMYCIN INCREASES PROTEASOME ACTIVITY IN THE BRAIN
The most pronounced effects to proteasome activity were evi-
dent in the brain suggesting that it is not the rapamycin directly
inducing these changes but rather the down-stream signaling
it induces in rapamycin-responsive tissues. In contrast to the
potential detrimental effects of rapamycin seen in visceral fat pro-
teolytic function, the increase of PMDS in the brain could be
beneficial and could suggest that organisms selectively protect cer-
tain more vulnerable tissues. Here, we observe that rapamycin
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FIGURE 12 | Response of the proteasome-chaperone network differs
between the brain and periphery. (A) Rapamycin treatment may stimulate
AKT in the brain, increasing proteasome-related chaperones through rp-S6
top-dependent translation and a non-cannonical stress response pathway
(red-dashed arrows) ultimately increasing proteasome activity in the female
brain. (B) In contrast, visceral fat shows a suppression of the mTOR network,
reduction of the HSF1 chaperone response, and a decrease in proteasome
activity.
induced an increase in proteasome activity, a phenotype com-
monly observed in long-lived species in the periphery as well
as in the brain (Chondrogianni et al., 2000; Rodriguez et al.,
2012; Edrey et al., 2014). Brain lysates from treated females
showed both an increase in ChTL and TL activity (Figures 1, 2)
as well as significant increases in 26S proteasome content on
non-denaturing gels (Figure 2). Proteasome-related chaperones
HSP70, C-terminal HSP-interacting protein (CHIP), RPT5, and
HSP25 also showed significant increases in rapamycin-treated
samples compared to control (Figure 5). Further, α7, RPT5,HSF1,
and HSP25correlated strongly with higher levels of proteasome
activity (Figure 11) in the cluster analysis. Other studies exam-
ining brains from rapamycin-treated mice have seen a similar
enhancement of protein homeostasis and/or the HSP system
(Spilman et al., 2010; Pierce et al., 2013; Orr et al., 2014). For
example, rapamycin-fed mice showed the enhanced expression
of the small chaperone gene, alpha-crystallin B chain (CRYAB)
in the brains of a mouse Alzheimer’s model (Pierce et al., 2013).
Further, crossing this model with an HSF1-transgenic mouse
(Pierce et al., 2010), which showed increased HSF1, HSP90, and
CryAB, reduced toxic brain amyloid-β levels and improved cogni-
tive function (Pierce et al., 2013). Interestingly, we did not see an
increase inHSF1 in brain tissue with rapamycin treatment though
cluster analyses suggested a correlation (Figures 5, 11). However,
several chaperones showed increases in rapamycin-treated female
brain samples (i.e., HSP70, CHIP, HSP25) suggesting both HSF1
and non-canonical upregulation of HSPs. One possibility is that
if rapamycin indeed inhibits proteasome activity in vivo as sug-
gested by in vitro studies (Osmulski and Gaczynska, 2013) an
alternate heat shock factor such as HSF2 may be triggered induc-
ing the same set of chaperones as HSF1 (Mathew et al., 1998).
The differences seen between the effects of rapamycin on the
brain and peripheral tissues also suggests a tissue-specific decou-
pling of rapamycin function. In a study in which mice genetically
mutated to serve as transgenic mouse models for Alzheimer’s
disease a tissue-specific decoupling of rapamycin effects were
observed when these mice were fed a high sucrose diet and
developed insulin resistance. While the exacerbation of plaques
were ameliorated by the simultaneous treatment with rapamycin,
rapamycin had no effect on peripheral insulin resistance and liver
protein levels (Orr et al., 2014).
In this study, we did not examine markers of autophagy.
Counter-intuitively, a previous investigation reports that,
autophagy in brain tissue lysates was not increased in rapamycin-
treated non-transgenic mice but only was manifest in animals
genetically engineered to express high levels of amyloid-β or tau
(Spilman et al., 2010; Orr et al., 2014). So while autophagy may
have a key role in reducing aggregates from disease pathologies,
non-aggregated protein degradation may instead be enhanced
by the PMDS. The increase in chaperone-E3 ligase CHIP in the
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brain and a significant decline in liver tissue (Figure 5) may
hold a clue. CHIP has been shown to be essential in modulating
oxidative load and degradation of oxidized proteins through the
PMDS as well as act as the E3 ligase for the degradation of tau,
parkin, and polyglutamine expansions in brain tissue (Dickey
et al., 2007; Sisoula and Gonos, 2011). As such, in the brain
chronic rapamycin treatment could trigger an E3 ligase like CHIP
to protect against proteotoxic stress, increasing the translation
of chaperone proteins and the proteasome-mediated, protein
degradation machinery to maintain protein equilibrium.
CHANGES IN mTOR SIGNALING CORRELATE WITH SEX AND TISSUE
DIFFERENCES
In both female brain and fat tissues the mTOR pathway proteins,
as expected, showed the most changes with rapamycin-treatment
(Figures 3, 7; Table 1). However, while the changes in female fat
samples suggest rapamycin blocks mTOR signaling, rapamycin-
mediated changes in the brain did not (Figures 6, 9; Table 1)
(reviewed in Wullschleger et al., 2006). Rather, these data suggest
that mTOR remains active in the brain, and that the inhibitory
effects of rapamycin are suppressed in brain tissue. This uncou-
pling of brain and peripheral effects on mTOR was unexpected
but could also explain the lack of increased levels of autophagy
in the brain of rapamycin-treated control animals seen in previ-
ous studies (Spilman et al., 2010; Orr et al., 2014). Further, the
increase in p-rpS6 in the female brain (Figure 6) was very dif-
ferent to what was observed in female fat (Figure 9) or in the
intestine of rapamycin-treated familial adenomatous polyposis
mice both which showed a decrease in the phosphorylation
state (ratio of phosphorylated to non-phosphorylated protein)
of rp-S6 and other mTOR signaling molecules (Hasty et al.,
2014). This paradox may be linked to the increase in both total
and phosphorylated AKT (Figure 6, Table 1). A similar induced
activation of AKT leading to a resistance of rapamycin treat-
ment has been observed in human lung cancer cells and human
rhabdomyosarcoma cell lines and in rodent cells overexpress-
ing insulin-like growth factor (IGF) II (Sun et al., 2005; Wan
et al., 2007). Unlike these cell systems, whereby the phospho-
rylation of both downstream mTOR targets S6K1 and 4EBP1
were suppressed, this was not observed in brain lysates from
rapamycin-treated old females in this study (Figure 6). Instead we
observed an increase in phosphorylated ribosomal protein S6, the
target of S6K1 (Figure 6), responsible for 5′ terminal oligopyrim-
idine (TOP)-dependent translation (Wullschleger et al., 2006).
Further, there was a decline in the phosphorylation state of 4EBP1
(Figure 6) which is responsible for control of cap-dependent
translation (Wullschleger et al., 2006) and inhibition of TOP-
dependent translation (Thoreen et al., 2012). This may be also
be reflected by the cluster analysis correlation of low 4EBP1
with proteasome activity (Figure 11). These changes in transla-
tional control suggest a focus on TOP-dependent translation, and
have further repercussions on the PMDS, as several proteasome-
related HSP mRNAs can be preferentially translated through
TOP-dependent translation during stress (Cuesta et al., 2000;
Pierce et al., 2013). Conversely, in fat we observed a decline in
phosphorylated rp-S6 and an increase in the phosphorylation
state of 4EBP1 suggesting a decrease in translation (Figure 9)
(Thoreen et al., 2012) that could in turn influence the observed
reduction of proteasome activity (Figure 1).
Phosphorylation of AKT also protects against the apoptotic
effects of proteasome inhibition further linking PMDS to the
AKT cell survival program (Yu et al., 2006; Zanotto-Filho et al.,
2012). As total AKT is also induced by 17-β estradiol (Haynes
et al., 2000), this may explain why rapamycin-treated female ani-
mals have more robust effects when treated by the drug. Taken
together, the sex-specific increase seen in brains of rapamycin
treated mice in our comprehensive measures of proteasome
activity could be linked to a sex-dependent change in AKT
signaling driven by mTOR regulation of the heat-shock pathway
through activated rp-s6 (as we observed in treated female brains;
Figure 3). Interestingly, mTOR signaling through rp-S6 has also
been shown to increase proteasome subunits with a dependence
on nuclear factor erythroid-derived 2-related factor 1 (NRF1)
(Zhang et al., 2014b). NRF1 also mediates the recovery of protea-
some activity after stress or proteotoxic insults (Radhakrishnan
et al., 2010; Balasubramanian et al., 2012).
CONCLUSIONS
Our data indicate that the sexually dimorphic effects of lifespan
extension induced by rapamycin (Harrison et al., 2009; Fok et al.,
2014; Miller et al., 2014; Zhang et al., 2014a) may be linked to sex
differences in tissue-specific responsiveness of the regulators and
components of mTOR, HSPs and PMDS pathways. Proteolytic
activity is augmented in the brain facilitating more efficient
removal of damaged or unfolded proteins, and as a consequence
thereof, improved brain structural and functional integrity. This
protective response to rapamycin treatment in brain tissue is
uncoupled from that of the response in peripheral fat tissue. The
latter, appears to be left more vulnerable to the potentially detri-
mental peripheral proteotoxic effects of rapamycin (Wilkinson
et al., 2012; Ponticelli, 2014; Zhang et al., 2014a). A proposed
summary of what happens to the PMDS in female brain vs.
the periphery (specifically visceral fat) with rapamycin treatment
is shown in Figure 12. Here we show that rapamycin appears
to influence up- stream regulators of the proteasome-chaperone
network through stimulation of the AKT pathway (Figure 12).
Defining how the AKT pathway is stimulated or repressed in vari-
ous tissues in a sex-dependent manner can give us insight on how
to better understand rapamycin’s effects in a therapeutic context.
Upstream regulators of the PMDS including E3 ligases such as
CHIP such as HSF1, 2 or NRF1 could be activated or suppressed
by the AKT stress response in a sex-dependent manner thereby
differentially affecting proteostasis in peripheral and brain tis-
sues. Maintenance of protein homeostasis in the female brainmay
play a pivotal role in the extended longevity observed only in the
rapamycin-treated female C57BL6 mice.
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